67Cu-SAR-bisPSMA not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1/2
- “The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.”In the company’s words, NCT04868604 on ClinicalTrials.gov
Other drugs for Prostatic Neoplasms, Castration-Resistant
- PasritamigJohnson & Johnson (Janssen) · Phase 3
- JNJ-87189401Johnson & Johnson (Janssen) · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- AAA617Novartis · Phase 2
- JSB462Novartis · Phase 2
- GedatolisibCelcuity Inc · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Sep 2026 | 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026